BMS-Celgene merger chances improve with backing from proxy advisers
When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up. Institutional Shareholder Services and Glass Lewis both said Friday that they’re backing the transaction. ISS pointed to deal’s “sound” strategic rationale and cost-cutting potential, while Glass Lewis said the buy “presents the opportunity for potentially… Read More »